Retrospective study for efficacy and safety of first generation EGFR-TKI plus Apatinib in treating advanced NSCLC after EGFR-TKI treatment failure
Latest Information Update: 05 Mar 2021
At a glance
- Drugs Rivoceranib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 05 Mar 2021 New trial record
- 31 Jan 2021 Results presented at the 2020 World Conference on Lung Cancer